Mandate

Vinge Advises Sunstone Capital on the Investment in CMC Contrast

February 27, 2008

Vinge advises Sunstone Capital on the investment in CMC Contrast. CMC Contrast develops the CMC 001 product. The product can be found on the market for international pharmaceuticals. The investment will contribute to further the development of the product and continued clinical studies.

Sunstone Capital is represented by partner Johan Winnerblad joined by associate Jonas Bergström.

Related

Vinge advises the founders of Modular Finance in connection with a transaction with Sprints

Vinge advises the founders of Modular Finance in connection with a sale of approximately 40% of the shares in the company to Sprints.
December 08, 2023

Vinge has advised Oxx in connection with the establishment of Oxx II

Oxx closes its second fund generation with USD 190 million in commitments from an international investor base, and thereby increases the fund size by 40% since its latest fund announcement.
December 07, 2023

Vinge has advised Cell Impact in connection with its rights issue

Vinge has advised Cell Impact AB (publ) in connection with a partly guaranteed rights issue which will provide Cell Impact with issue proceeds of SEK 129 million before deduction of transaction costs
December 06, 2023